Session » Cytokines & Cell Trafficking Poster (0508–0516)

Date: Sunday, November 7, 2021

Time: 8:30AM-10:30AM

Meeting: ACR Convergence 2021

8:30AM-10:30AM: Abstract Number: 0516

Dual Fibroblast Transdifferentiation Mediated by Type I Interferon: Application to Anti-Ro Mediated Congenital Heart Block

8:30AM-10:30AM: Abstract Number: 0514

Extracellular Sulfatase-2 Mediates TNF-α Inflammatory Signaling in Human Rheumatoid Arthritis Synovial Fibroblasts

8:30AM-10:30AM: Abstract Number: 0510

Fibrinogen Modified with Malondialdehyde-Acetaldehyde Adduct (MAA) And/or Citrulline (CIT) Induces Unique Cellular Responses in Human RA Synoviocytes

8:30AM-10:30AM: Abstract Number: 0512

Peficitinib and Filgotinib Inhibit Angiogenesis via Suppression of VEGF Production in Rheumatoid Arthritis Fibroblast-like Synoviocytes

8:30AM-10:30AM: Abstract Number: 0509

Selective Inhibition of Tyrosine Kinase 2 with Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors

8:30AM-10:30AM: Abstract Number: 0513

Spirulina Activates IFNγ via TLR4 in Dermatomyositis Skin and Peripheral Blood

8:30AM-10:30AM: Abstract Number: 0515

The Extracellular Sulfatase-2 Inhibitor OKN-007 Abrogates TNF-α-induced Inflammatory Mediators in Human Rheumatoid Arthritis Synovial Fibroblasts

8:30AM-10:30AM: Abstract Number: 0508

The Impact of Macrophages Stimulated with Malondialdehyde-Acetaldehyde And/or Citrulline Modified Proteins on Fibroblasts Activation

8:30AM-10:30AM: Abstract Number: 0511

Tumor Necrosis Factor-α Modulates Endothelial-to-mesenchymal Transition and Increases Protein Tyrosine Phosphatase 1B

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].